Ex­clu­sive: Two ex-Re­cur­sion lead­ers start Noetik in a bid to fix the bro­ken fun­nel in can­cer drug re­search

Two for­mer lead­ers of Re­cur­sion Phar­ma­ceu­ti­cals have start­ed their own biotech start­up, hop­ing to bring a sim­i­lar da­ta-ob­sessed men­tal­i­ty to can­cer re­search.

The San Fran­cis­co-based com­pa­ny called Noetik launched Thurs­day, an­nounc­ing a $14 mil­lion seed round led by DCVC. Its two co-founders are CEO Ron Al­fa, for­mer­ly head of re­search at Re­cur­sion, and CSO Ja­cob Ri­nal­di, who pre­vi­ous­ly led on­col­o­gy re­search at the Utah biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER